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Abstract  
 
Background: Several selected population-based studies have emphasized the significance of 
resting heart rate as an independent cardiovascular risk factor. However, there are no data 
available for using resting heart rate as a cardiovascular risk predictor in contemporary 
primary care. Thus, the aim of our analysis was to examine the clinical value of the 
measurement of resting heart rate in a large, unselected population-based cohort of primary 
care subjects under the conditions of contemporary primary prevention.  
Design: Prospective, population-based cohort study.  
Methods: We examined a subgroup of 5320 unselected primary care subjects free of coronary 
artery disease from the nationwide, longitudinal Diabetes Cardiovascular Risk Evaluation 
Targets and Essential Data for Commitment of Treatment (DETECT) cohort study, which was 
conducted from 2003 to 2008.  
Results: During the follow-up time of 5 years, 258 events were reported. Elevated resting 
heart rate was not associated with an increased risk for cardiovascular events (HR=0.75, 
p=0.394), cardiovascular mortality (HR=0.71, p=0.616) or major cardiovascular events 
(HR=0.77, p=0.376). By cross-sectional analysis, elevated heart rate clustered with markers of 
the metabolic syndrome, like increased blood pressure (systolic: OR=5.54, p<0.0001; 
diastolic: OR=3.82, p<0.0001), elevated fasting plasma glucose levels (OR=8.84, p<0.0001), 
hypertriglyceridaemia (OR=22.16, p=0.001), and obesity (body mass index OR=0.89, 
p<0.0001). Assessment of resting heart rate in clinical practice had minimal and non-
significant additional prognostic value compared to established cardiovascular risk factors as 
judged by C statistics (C=0.001, p=0.979).  
Conclusion: The measurement of resting heart rate in the daily routine of primary care does 
not provide incremental prognostic information for cardiovascular risk stratification.  
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Introduction  
 
Several epidemiological studies have suggested that an elevated heart rate measured at rest 
might be a predictor of cardiovascular1,2 and non-cardiovascular mortality.3,4 Especially the 
recently published BEAUTIFUL study has re-ignited the interest in the prognostic 
significance of resting heart rate: although lowering resting heart rate by ivabradine on top of 
beta-blocker therapy did not have a significant effect on the combined endpoint of 
cardiovascular morbidity and mortality in patients with coronary artery disease and left-
ventricular dysfunction,5 a sub-group analysis within the placebo arm of the trial showed that 
a high resting heart rate was a strong independent risk factor for the aforementioned 
endpoint.6  
 
Previous studies in the general population including subjects without known coronary artery 
disease have produced discrepant findings regarding the significance of resting heart rate as 
an independent cardiovascular risk factor: analyses of population subgroups such as women,1 
subjects within a narrow age-range7 or specific occupations, such as industrial workers or 
civil servants,4,8 revealed a significant influence of resting heart rate on coronary events and 
cardiovascular death. However, in the so far largest study,7 the predictive power of resting 
heart rate was reduced after adjustment for cardiovascular risk factors. None of the large-scale 
population-based analyses accounted for primary prevention measures. Thus, it is still unclear 
whether resting heart rate itself causes higher mortality or whether there is merely an 
association between resting heart rate and mortality.9  
 
Finally, since heart rate is a highly variable biological marker,10 the question arises as to 
which extent the results, which were obtained under standardized study conditions, can be 
extended to primary prevention, and to what degree the predictive value of a resting heart rate 
measurement in everyday practice is significant for cardiovascular risk stratification.  
 
Therefore, the aim of our analysis was to determine the prognostic significance of resting 
heart rate as an independent cardiovascular risk factor assessed in a large representative 
primary care population of individuals free of coronary artery disease under the conditions of 
contemporary primary prevention. Furthermore, we aimed to assess to which extent a single 
measurement of heart rate, as measured by general physicians in the context of their everyday 
work, adds relevant prognostic information for cardiovascular risk stratification in this 
population of primary care subjects.  
 
Materials and methods  
 
Study population  
 
The Diabetes Cardiovascular Risk Evaluation Targets and Essential Data for Commitment of 
Treatment (DETECT) – trial is a large multistage prospective longitudinal study. The baseline 
study consisted of a nationwide representative sample of doctors with primary care functions 
(medical practitioners, general practitioners, general internists) and included a total of 55,518 
unselected consecutive patients recruited on two predefined half-day cut-off dates in 3188 
primary care offices in Germany. Subjects were included into the present study during a 
routine consultation with the primary physician for a good health examination or for treatment 
of an acute or chronic non-cardiac disease.  
 
A representative partial sample of 7519 subjects was randomly chosen in 1000 primary care 
offices and evaluated over a 5-year time period with two assessment points at 12 months and 
5 years after inclusion. For inclusion into the present analysis, study participants had to be 
free of any history of prior myocardial infarction, known coronary artery disease, documented 
stroke, clinical signs of systolic or diastolic heart failure, and/or chronic kidney disease 
requiring haemodialysis at baseline.  
 
The DETECT survey received the approval of the Ethics Committee of the Carl Gustav Carus 
Medical Faculty at the Technical University of Dresden (AZ: EK149092003; 16 September 
2003) and registered at clinicaltrials.gov (NCT: 01076608).  
 
Measurements  
 
Details on the methods used in the DETECT study have been described elsewhere.11 The 
baseline examination consisted of a standardized medical history, a physical examination, and 
a laboratory assessment. Subjects additionally completed a self-administered questionnaire, 
which was used to assess demographic data, smoking history, family history, and information 
on duration and severity of cardiovascular risk factors and existing medical as well as non-
medical treatment. Physicians also completed a questionnaire concerning their patients’ 
symptoms, diagnoses, treatments, and health behaviour. Assessment tools with established 
reliability and validity were used. Trained staff measured blood pressure according to the 
guidelines of the German Hypertension League.  
 
Heart rate was measured the way primary care physicians assess this parameter in their daily 
routine, after an adequate resting period. The same examinations were repeated at the 1-year 
follow-up.  
 
Endpoints  
 
State of health and medical history during follow up were ascertained at the conclusion of the 
trial as part of the final assessment in 2008. The following endpoints were documented: all 
cause mortality, mortality of cardiovascular cause, occurrence of a myocardial infarction, and 
manifestation of coronary artery disease as evidenced by the necessity for coronary 
revascularization by either coronary artery bypass graft (CABG) or percutaneous coronary 
intervention (PCI). Deaths and known causes of deaths were determined by the treating 
primary care physicians and supplemented by consulting the national cause of death registry. 
For analysis, a combined endpoint of ‘major cardiovascular events’ was used including death 
from cardiovascular causes, non-fatal myocardial infarction, and necessity for coronary 
revascularization by CABG surgery or PCI.  
 
Statistical analyses  
 
All participants were subdivided into quartiles based on resting heart rate, as measured by the 
primary physician. The association of resting heart rate with the different outcomes was 
investigated with the use of Cox proportional hazards regression. Besides crude analysis, 
hazard ratios (HRs) were adjusted for confounding variables, which have previously been 
shown to influence resting heart rate.12,13 These were age, gender, atrial fibrillation, and rate 
control medication with beta-blockers or calcium-channel blockers. HRs were additionally 
adjusted for established cardiovascular risk factors such as diabetes mellitus, hypertension, 
smoking status, hyperlipidaemia, and body mass index. In order to evaluate the significance 
of change in resting heart rate over time, measurements of resting heart rate were performed 
at the 1-year follow-up and compared to the baseline values. The influence of absolute 
changes in quartiles of resting heart rate as well as the influence of an increase or decrease of 
resting heart rate between baseline and the first follow-up time point at 12 months were 
determined by assessment of HRs.  
 
The association of resting heart rate and the established cardiovascular risk factors was 
assessed by odds ratios, which were determined by multiple logistic regression analysis. To 
evaluate the prognostic value of resting heart rate measurement compared to risk stratification 
using the established cardiovascular risk factors, the C statistic was calculated. The estimates 
of the C statistic after Cox regression models (with 95% confidence intervals) for 
conventional cardiovascular risk factors, with and without resting heart rate as a dichotomous 
variable (heart rate above mean value), were calculated to assess model discrimination. 
Results are presented as mean ± standard deviation. p-values <0.05 from two-sided test were 
considered to indicate statistical significance. All statistical analyses were conducted with the 
use of STATA 11.14  
 
 
Results  
 
Of 7519 patients, 5320 patients with a complete data set and without known coronary artery 
disease (CAD) were included in the final analysis. Their baseline characteristics are shown in 
Table 1. The majority of participants was female, the mean age was 55.9 ± 13.7 years and 
1852 participants (34.8%) had arterial hypertension. Antihypertensive treatment consisted of 
angiotensin-converting enzyme inhibitors/angiotensin receptor blocker (26%), beta-blockers 
(20.4%), calcium- channel blockers (10.3%), or diuretics (12.8%). For hyperlipidaemia, 
10.9% were treated with a statin, and 3.5% of participants suffered from insulin-dependent 
diabetes mellitus. The average resting heart rate was 72.8±9.9 beats per minute (bpm) at 
inclusion into the study and 72.3 bpm ± 9.8 at the follow-up examination after 1 year. Within 
the study cohort, the mean estimated 10-year risk for a serious cardiovascular event calculated 
by the Framingham risk score was 13.8% ± 5.3. The main reason for seeing a primary care 
physician was for a check-up examination.  
 
During the follow-up time of 5 years, a total number of 258 incident events (4.85%) was 
observed: There were 137 (2.58%) deaths in total; of these, 22 (0.41%) deaths were of 
cardiac-related cause (myocardial infarction, sudden cardiac death). In 121 (2.27%) subjects, 
a cardiovascular event (non-fatal myocardial infarction, revascularization by CABG or PCI) 
occurred.  
 
Figure 1 shows the relative risk of the study cohort for the endpoints all-cause mortality, 
cardiovascular mortality, occurrence of a serious cardiovascular event (non-fatal myocardial 
infarction or revascularization by CABG or PCI), and major cardiovascular event (myocardial 
infarction, revascularization by CABG or PCI, or death from cardiovascular cause) within the 
5-year follow-up period. There was no significantly increased risk as expressed by HRs in 
higher quartiles of heart rate compared to the lowest quartile of heart rate, except for all-cause 
mortality of women, which was significantly higher (HR=2.99; p=0.011, crude) in the 
subgroup of women within the highest quartile of resting heart rate.  
 
After adjustment for cofactors that influence heart rate (age, gender, atrial fibrillation, and rate 
control medication) and further adjustment for established cardiovascular risk factors 
(hypertension, diabetes mellitus, smoking status, family history, hyperlipidaemia and body 
mass index), no detectable influence of resting heart rate on any of the study endpoints was 
observed (Table 2).  
 
While classical, established cardiovascular risk factors, such as arterial hypertension 
(HR=4.80; p<0.0001), hyperlipidaemia (HR=2.16; p<0.0001), and diabetes mellitus 
(HR=2.87; p<0.0001), demonstrated significantly increased HRs within the study cohort, 
neither a cut-off value of 70 bpm nor a study specific cut-off of mean heart rate (72.8 bpm) 
was associated with an increase of risk for major cardiovascular events in a crude statistical 
model or after adjustment for age and gender (Table 3).  
 
Since a one-time measurement of resting heart rate in primary care did not show an 
association with the various endpoints in the 5-year follow-up period, the relative risk of 
repeated heart rate measurements was determined. To assess the prognostic value of a 
repeated measurement of resting heart rate, we used the data obtained at the first follow-up 
after 1 year (2004) (n=4472). We determined the absolute change of resting heart rate as well 
as an increase or decrease of heart rate, and calculated the relative risk of changes in heart rate 
during repeated measurements for onset of major cardiovascular events during follow-up. As 
shown in Table 4, there was no significant influence on relative risk for the combined 
endpoint of a major cardiovascular event within the remaining follow-up period of 4 years. 
Even for a potentially high-risk cohort of primary care subjects, who had repeatedly elevated 
resting heart rate in the highest quartile, we could not observe an increase of risk (HR=1.09; 
p=0.862 crude) for a major cardiovascular event.  
 
In order to characterize patients within the quartiles of heart rate, we performed a cross-
sectional analysis between heart rate quartiles and established cardiovascular risk factors 
(Table 5). The prevalence of cardiovascular risk factors, such as smoking (OR=1.54; 
p<0.0001), hypertriglyceridaemia (OR=22.16; p= 0.001), and diabetes mellitus (OR=1.70; 
p<0.0001) was significantly higher in subjects within the highest quartile of heart rate 
compared to the lowest quartile of heart rate. Likewise, the mean systolic and diastolic blood 
pressure value as well as obesity increased significantly with increasing quartiles of resting 
heart rate.  
 
To finally evaluate the significance of a single measurement of resting heart rate in primary 
care compared to risk stratification by established cardiovascular risk factors, we determined 
the additive predictive value of resting heart rate by C statistic for Cox regression models. As 
shown in Table 6, the additional measurement of heart rate had no additional effect on risk 
stratification compared to a model based only on established cardiovascular risk factors, 
including age, gender, systolic and diastolic blood pressure, hyperlipidaemia, diabetes 
mellitus, obesity, smoking status, and family history of coronary artery disease (C=0.803; 
p=0.979).  
 
 
Discussion  
 
In a representative cohort of primary care subjects without existing coronary artery disease 
(CAD) at baseline, studied under the conditions of contemporary primary prevention, the one-
time measurement of resting heart rate in the primary physicians’ office did not provide 
prognostic information on cardiovascular outcome over and above classical risk factors for 
CAD. Resting heart rate in this setting was not an independent cardiovascular risk factor for 
different endpoints of mortality and cardiovascular morbidity, but was associated with 
established cardiovascular risk.  
 
 
 
Significance of resting heart rate as a risk factor in primary prevention  
 
A multitude of recent studies emphasized the potential significance of resting heart rate as an 
independent cardiovascular risk factor. While the influence of resting heart rate on the 
progression of existing cardiac disease has been highlighted impressively in several 
epidemiological analyses15,16 and clinical trials,6,17 the data available for resting heart rate as a 
cardiovascular risk factor in subjects free of coronary artery disease is inconclusive. In one of 
the largest analysis so far in nearly 380,000 subjects, all within one age-group of 40–45 years, 
the predictive power of resting heart rate for cardiovascular mortality was lost after 
adjustment for other cardiovascular risk factors.7 In contrast, a large trial including only 
postmenopausal women free of cardiovascular disease emphasized the role of heart rate as an 
independent predictor of cardiovascular death and non-fatal myocardial infarction.1 Nauman 
et al.18 reported a strong association between resting heart rate and cardiovascular mortality in 
a study cohort of about 50,000 patients followed-up for over 18 years. However, the study 
was initiated in the early 1980s, a time when cardiovascular primary prevention strategies did 
not yet include angiotensin-converting enzyme inhibitors or statin therapy, which were shown 
to play an important role in reducing cardiovascular mortality in primary prevention.19–21 
Moreover, a significant change of the cardiovascular risk profile is seen over the past two 
decades.22 In the present study, the mean body mass index was 2 kg/m2 higher and there was 
a higher proportion of other cardiovascular risk factors compared to the study by Nauman et 
al.18  
 
Elevated heart rate is well established to cluster with measures of the metabolic syndrome, 
e.g. obesity, increased diastolic and systolic blood pressures, dyslipidaemia, and elevated 
insulin and glucose levels. Indeed, the present study confirmed the significant correlation 
between different clusters of the insulin resistance syndrome and resting heart rate, thus 
further supporting previous findings that the metabolic syndrome is characterized by 
sympathetic overdrive and that this condition is mirrored by an increase in heart rate.23–25 
Finally, cardiac autonomic neuropathy, as a long-term consequence of metabolic 
dysregulation and diabetic metabolism, provides another mechanistic link of elevated heart 
rate and the metabolic syndrome.26 Taken together, the data derived from the present study 
suggest that increased heart rate rather appears to be a ‘risk marker’ correlating with features 
of the metabolic syndrome than an independent cardiovascular ‘risk factor’ in a contemporary 
primary prevention cohort.  
 
Prognostic information of the measurement of resting heart rate in primary care  
 
Contrary to previous studies, an important goal of our study was not only to investigate the 
association between resting heart rate and different endpoints, but rather to test the practical 
implications of measuring resting heart rate by primary physicians the way it is assessed in 
their daily routine.  
 
The clinical value of a marker should be assessed by its effect on patient management and 
outcome and by the degree of incremental prognostic information it provides.27 All existing 
studies that have emphasized the importance and prognostic significance of resting heart rate 
are based on heart rate measurements under standardized conditions, which took into account 
well-known confounders of heart rate assessment.10,28  
 
In our analysis, the measurement of resting heart rate was performed as realistically as 
possible in the setting of primary physicians’ offices, and in this setting no additive predictive 
value of resting heart rate on top of established cardiovascular risk factors could be identified. 
This finding leads us to question the conclusion of other studies that emphasize resting heart 
rate as an independent risk factor, as it is difficult for primary care physicians to validly assess 
resting heart rate within their daily routine and without the possibility of reproducing 
standardized conditions for heart rate measurement. This is emphasized by our findings that 
repetitive measurements of heart rate by the same primary physician do not lead to improved 
risk stratification over a one-time measurement.  
 
Limitations  
 
Some limitations of our analysis merit discussion. First, follow-up time was 5 years in the 
present study, whereas previous community-based studies reported on follow-up times 
ranging up to 18 years.18 Given the rapid developments in pharmacological therapies 
emerging in primary prevention over the last decade, we felt it to be important to limit the 
follow-up observation period in order to avoid potential confounding effects of changing 
clinical practice in primary prevention strategies, e.g. the emergence of statin or angiotensin-
converting enzyme inhibitor/angiotensin receptor blocker therapy being used across a broad 
range of cardiovascular risk since the late 1990s and early 2000s. Second, according to a 
recent recommendation, we restricted our combined endpoint to the occurrence of myocardial 
infarction, coronary revascularization by PCI or CABG and cardiovascular mortality due to 
sudden cardiac death or fatal myocardial infarction. We do believe that this is an appropriate 
choice given that this combined endpoint has not only been used in previous risk-stratifying 
models, but is also a universally accepted endpoint used in major cardiovascular clinical trials 
evaluating pharmacological interventions for primary prevention.29  
 
Finally, the rather moderate number of events during 5 years of follow-up may have limited 
the statistical power of our analysis. While power calculations using the sample size and event 
rates of the present study revealed that the conclusions drawn appear to be statistically solid 
for the male study population, there remain some uncertainties regarding the female study 
cohort. Indeed, the association between allcause mortality and resting heart rate was of 
borderline statistical significance (p=0.055) in the female cohort. Thus, the rather moderate 
number of deaths in the female study cohort may have obscured a significant association. In 
addition, previous studies have demonstrated a weak, albeit statistically significant association 
between all-cause mortality and resting heart rate in female subjects.14.30 Taken together, we 
cannot fully exclude that assessing resting heart rate might be useful in female primary care 
subjects, and it might be worthwhile to examine potential gender differences in the utility of 
resting heart rate to predict prognosis.  
 
 
Conclusions  
 
We conclude that the measurement of heart rate in the daily routine of primary care does not 
provide relevant prognostic information for cardiovascular outcome. However, we detected an 
association between increased heart rate and parameters of the metabolic syndrome.  
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